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ORIGINAL RESEARCH
Racial Disparities in Modifiable Risk Factors 
and Statin Usage in Black Patients With 
Familial Hypercholesterolemia
Anandita Agarwala , MD; Nathan Bekele, MD; Elena Deych, MS; Michael W. Rich, MD; Aliza Hussain, MD; 
Laney K. Jones , PharmD, MPH; Amy C. Sturm , MS; Karen Aspry, MD, MS; Elizabeth Nowak, BS;  
Zahid Ahmad, MD; Christie M. Ballantyne , MD; Anne C. Goldberg, MD
BACKGROUND: Black men and women are at higher risk for, and suffer greater morbidity and mortality from, atherosclerotic 
cardiovascular disease (ASCVD) compared with adults of European Ancestry (EA). Black patients with familial hypercholes-
terolemia are at particularly high risk for ASCVD complications because of lifelong exposure to elevated levels of low- density- 
lipoprotein cholesterol.
METHODS AND RESULTS: This retrospective study analyzed ASCVD prevalence and risk factors in 808 adults with heterozygous 
familial hypercholesterolemia from 5 US- based lipid clinics, and compared findings in Black versus EA patients. Multivariate 
logistic regression models were used to determine the strongest predictors of ASCVD as a function of race. No significant 
difference was noted in the prevalence of ASCVD in Black versus EA patients with familial hypercholesterolemia (39% versus 
32%, respectively; P=0.15). However, Black versus EA patients had significantly greater prevalence of modifiable risk fac-
tors, including body mass index (mean, 32±7 kg/m2 versus 29±6 kg/m2; P<0.001), hypertension (82% versus 50%; P<0.001), 
diabetes (39% versus 15%; P<0.001), and current smoking (16% versus 8%; P=0.006). Black versus EA patients also had 
significantly lower usage of statins (61% versus 73%; P=0.004) and other lipid- lowering agents. In a fully adjusted multivariate 
model, race was not independently associated with ASCVD (odds ratio, 0.92; 95% CI, 0.60– 1.49; P=0.72).
CONCLUSIONS: The strongest predictors of ASCVD in Black patients with familial hypercholesterolemia were hypertension 
and cigarette smoking. These data support wider usage of statins and other lipid- lowering therapies and greater attention to 
modifiable risk, specifically blood pressure management and smoking cessation.
Key Words: familial hypercholesterolemia ■ hypertension ■ racial disparities ■ smoking
Black men and women are at higher risk for ath-erosclerotic cardiovascular disease (ASCVD) and, when diagnosed with ASCVD, have greater mor-
bidity and mortality compared with their counterparts of 
European ancestry (EA). In 2010, the self- reported prev-
alence of diagnosed coronary heart disease was 6.5% 
in Black individuals compared with 5.8% in individuals 
of EA.1,2 Between 2006 and 2014, data from the ARIC 
(Atherosclerosis Risk in the Community) study showed 
that the incidence of myocardial infarction was higher for 
Black versus EA men at all ages, and the incidence in 
Black women was roughly equivalent to that of EA men, 
and higher after age 65.3 Black men and women are also 
less likely than other racial and ethnic groups to achieve 
ideal cardiovascular health metrics and have higher lev-
els of several physiologic risk factors, including hyper-
tension.4 Many of the differences in risk factors for and 
outcomes from cardiovascular disease between Black 
patients and those of EA have been attributed to social 
determinants of health, including social and structural 
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inequities in access to optimal health care, education, 
income, healthy food, and stable and healthy living en-
vironments, all of which negatively impact downstream 
behavioral and physiologic risk factors.
Familial hypercholesterolemia (FH) is a genetic lipo-
protein disorder with a frequency of about 1 in 250 in 
the population. FH leads to lifelong elevation of low- 
density lipoprotein cholesterol (LDL- C) levels.5 Patients 
with heterozygous FH have about a 20- fold increased 
risk of ASCVD and its complications. However, racial 
differences in the risk of ASCVD and its predictors in 
Black patients with FH compared with those of EA have 
not been well studied and might be higher in Black pa-
tients with FH because of higher baseline risk. We com-
pared the prevalence of, and risk factors for, ASCVD in 
Black patients with FH with those of EA with FH.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request to anandita.kulkarni@bswhealth.org.
Human and Animal Rights and Informed 
Consent
This article does not contain any studies with human or 
animal subjects performed by any of the authors.
Study Design
We retrospectively collected data on 808 adult patients 
under treatment for heterozygous FH at 5 US- based 
lipid clinics: Washington University in St Louis, Baylor 
College of Medicine, University of Texas Southwestern 
Medical Center at Dallas, Geisinger Health, and the 
Brown University Lifespan Hospital system. Institutional 
review board approval was obtained from all participat-
ing institutions. All data extraction was done by trained 
research assistants who extracted deidentified data 
into a dedicated study spreadsheet. The institutional 
review boards at each site approved of the protocol, 
and waivers were obtained for retrospective data col-
lection. Race was self- reported. Patients were diag-
nosed with either heterozygous or homozygous FH 
on the basis of validated clinical or genetic diagnostic 
criteria. Clinical diagnosis was based on, but was not 
limited to, Simon Broome, Dutch Lipid Clinic Network, 
MEDPED, or American Heart Association criteria. 
Patients included in this cohort either had genetically 
confirmed FH or had a possible, probable, or definite 
diagnosis per a clinical diagnostic score. The diagno-
sis of FH was made by the treating clinic based on 
validated clinical criteria or genetic testing. Given the 
heterogeneous means of diagnoses, patients with ei-
ther a clinical or genetic diagnosis were characterized 
as having FH, and no distinction was made between 
patients who had a clinical or genetic diagnosis for the 
scope of this analysis. Data were independently col-
lected at each of the participating clinical sites and ret-
rospectively compiled for this analysis.
Laboratory Values and Medical History
Variables
Demographic data, medical history, and laboratory 
values were ascertained by retrospective chart re-
view for current patients from the respective lipid clin-
ics that provided their information. Age was reported 
from the most recent clinic visit to the time of data col-
lection. Lipid measurements were obtained through 
standardized commercial or institutional laboratories. 
Laboratory measurements were reported as the most 
recent on- treatment values. Treated lipid values are 
reported for patients receiving pharmacologic lipid- 
lowering therapy. A history of ASCVD was defined 
through objective testing for coronary, peripheral, or 
cerebrovascular disease or a cardiovascular event, 
including angina, myocardial infarction, coronary an-
gioplasty, peripheral arterial surgery, claudication, 
CLINICAL PERSPECTIVE
What Is New?
• The present study demonstrates disparities in 
lipid treatment and lipid medication usage in 
Black patients with familial hypercholesterolemia 
compared with those of European ancestry, and 
higher residual risk for future atherosclerotic car-
diovascular disease in these patients attributable 
to racial differences in nearly all modifiable risk 
factors for atherosclerotic cardiovascular disease.
What Are the Clinical Implications?
• There is a need for greater attention to lipid medi-
cation usage and to reduction in residual risk in 
Black patients with familial hypercholesterolemia 
through aggressive prevention strategies focused 
on medication acquisition and adherence, smok-
ing cessation, and blood pressure management.
Nonstandard Abbreviations and Acronyms
ARIC Atherosclerosis Risk in the 
Community
CASCADE- FH Cascade Screening for 







 http://ahajournals.org by on Septem
ber 10, 2021
J Am Heart Assoc. 2021;10:e020890. DOI: 10.1161/JAHA.121.020890 3
Agarwala et al Racial Disparities in Black Patients With FH
peripheral angioplasty, transient ischemic attack, 
stroke, or carotid endarterectomy. Premature ASCVD 
was defined as age <55 years in men and <65 years 
in women. The presence of ASCVD was compre-
hensively assessed at the initial visit as well as read-
dressed at subsequent visits.
Statistical Analysis
The prevalence of ASCVD was evaluated in the entire 
cohort and stratified by race, that is, Black versus 
EA patients. Patients who did not identify as either 
Black or of EA were excluded from the analysis. 
The association of race with demographic and clini-
cal variables was assessed univariately using a chi- 
squared test for categorical variables and a t test for 
continuous variables. Triglycerides were compared 
using the Mann- Whitney U test because of nonnor-
mal distribution. Prediction of ASCVD was assessed 
in a generalized linear mixed- effects model with bi-
nomial distribution, where study center was modeled 
as a random effect to account for within- site correla-
tion. Missing data were imputed using multiple impu-
tation methodology (See Table  S1 for missing data 
variables). Multiple imputation was performed using 
the Multivariate Imputation by Chained Equations al-
gorithm in R (https://www.jstat soft.org/artic le/view/
v045i03), which allows for the imputation of both 
continuous and categorical variables. Missing values 
were imputed for body mass index (BMI), smoking, 
diabetes, and hypertension. The missing imputation 
values model included these variables, in addition to 
age, sex, and race. The imputation was done with 5 
imputed data sets. (Cholesterol values could not be 
imputed because they were not missing at random. 
Imputation of these values may have resulted in a bi-
ased estimate, as subjects who were not on treat-
ment were more likely to have missing both treated 
and untreated LDL- C values.) Two multivariable re-
gression models were fitted. The first model included 
age, sex, and race. The second model included 
race, age, sex, BMI, diabetes, hypertension, and cur-
rent smoking. In separate exploratory, hypothesis- 
generating models, the interaction of race with each 
clinical covariate was tested (data from this analysis 
are shown in the Figure). In addition, we assessed for 
the predictors of ASCVD stratified by race including 
all covariates. Standard regression diagnostics were 
performed. The results of the models using imputed 
data were confirmed in a sensitivity analysis includ-
ing complete cases only (not shown). The standard 
criteria of a 2- sided P value <0.05 for statistical sig-
nificance was used in this study. The analyses were 
performed using R statistical software version 4.0 
(R Foundation for Statistical Computing, Vienna, 
Austria).
RESULTS
Baseline characteristics of the 175 Black adult pa-
tients compared with 633 patients of EA are shown 
in Table  1. There was no significant difference in 
mean age between the 2 groups, and women out-
numbered men in both. The absolute LDL- C was 
above recommended thresholds in both Black and 
EA patients with FH. Fewer Black versus EA pa-
tients were on statins (61% versus 73%, respectively; 
P=0.004), ezetimibe (29% versus 38%, respectively; 
P=0.03), and PCSK9 (proprotein convertase subtili-
sin/kexin type 9) inhibitors (1% versus 12%, respec-
tively; P<0.001). Approximately 23% of patients in our 
study were not reported to be on any lipid- lowering 
therapy; 33% of Black patients were not on lipid- 
lowering therapy, while 21% of patients of EA were 
not on lipid- lowering therapy.
No significant difference was noted in the preva-
lence of ASCVD and premature ASCVD in Black ver-
sus EA patients with FH (39% compared with 33%, 
P=0.15; and 26% versus 21%, P=0.17, respectively). 
Nonlipid risk factors for ASCVD were significantly 
higher in Black patients with FH, who had higher mean 
BMI (32±7 kg/m2 versus 29±6 kg/m2 in EAs; P<0.001), 
hypertension (82% versus 50% in EA; P<0.001), dia-
betes (39% versus 15% in EAs; P<0.001), and rate of 
current smoking (16% of Black patients versus 8% of 
Figure 1. Forest plot of the interaction of each clinical 
variable by race.
*P value is for the interaction of clinical variable by race. There 
may be a potential difference by race in age and diabetes. We 
did not adjust for multiple testing, and these analyses were not 
prespecified. These analyses are exploratory and should be 




 http://ahajournals.org by on Septem
ber 10, 2021
J Am Heart Assoc. 2021;10:e020890. DOI: 10.1161/JAHA.121.020890 4
Agarwala et al Racial Disparities in Black Patients With FH
EA patients; P=0.006). Assessment of risk factors in 
Black patients with and without ASCVD revealed that 
those with ASCVD had no significantly higher preva-
lence of hypertension (89% versus 77%; P=0.075) but 
were significantly more likely to be current smokers 
(26% versus 9%; P=0.009) (Table 2). In a mixed- effects 
model, after multivariate adjustments for age and sex, 
race was independently associated with ASCVD (odds 
ratio, 1.60; 95% CI, 1.05– 2.44; P=0.028). However, 
after further adjustment for hypertension, smoking 
status, BMI, and diabetes, the association between 
race and ASCVD was attenuated and no longer statis-
tically significant (odds ratio, 0.92; 95% CI, 0.60– 1.49; 
P=0.72).
Age, female sex, hypertension, and current smoking 
remained significant predictors of ASCVD in patients 
with FH (Table 3). In a stratified multivariable regression 
model (Table  4), the strongest predictors of ASCVD 
in Black patients with FH were smoking and hyper-
tension (odds ratio, 3.63; 95% CI, 1.40– 10.38; P=0.01 
for current versus no smoking, and odds ratio, 3.25; 
95% CI, 1.11– 10.64; P=0.04 for hypertension versus no 
hypertension). In a sensitivity analysis, including only 
complete cases, the results were similar and the same 
variables were significant (data not shown).
The Figure shows a forest plot with odds ratios of 
all predictors by race, with BMI converted into a di-
chotomous obesity variable for ease of presentation. 
Interaction terms of each factor by race indicate po-
tential effect modification for age and diabetes by race. 
There may be a potential difference by race in age and 
diabetes. We did not adjust for multiple testing, and 
these analyses were not prespecified. These analyses 
are exploratory and should be investigated further in 
future studies.
DISCUSSION
In this cohort of 808 patients (175 Black adult pa-
tients compared with 633 adult patients of EA) with 
FH treated in specialized lipid clinics across several 
regions of the United States, Black patients with FH 
did not have a statistically significant higher prevalence 
of documented ASCVD compared with patients of 
EA. However, Black patients had a significantly higher 
prevalence of nonlipid risk factors for future ASCVD 
events, including hypertension, diabetes, and current 
smoking. Also, fewer Black versus EA patients with FH 
were on lipid- lowering medications, including statins, 
ezetimibe, and proprotein convertase subtilisin/kexin 
type 9 inhibitors. After multivariate adjustment for hy-
pertension, smoking status, BMI, and diabetes, race 
was not a significant predictor of ASCVD. On the other 
hand, traditional risk factors in Black patients with FH, 
including hypertension and current cigarette smoking, 
were significant predictors of ASCVD in multivariate 
models. These findings have important implications, as 
they show that traditional and modifiable nonlipid risk 
factors, including hypertension and current smoking, 
are highly prevalent and significant drivers of ASCVD 
risk in Black patients with FH.
This study also demonstrated significant gaps in 
the use of statins and other lipid- lowering therapies in 
Black patients versus EA patients with FH, suggest-
ing lower treatment and/or adherence. This finding is 
particularly concerning since observational data have 
shown that statin treatment is associated with signifi-
cant reductions in ASCVD risk in FH, and randomized 
trials of proprotein convertase subtilisin/kexin type 9 in-
hibitors in patients with FH have demonstrated further 
reductions in ASCVD risk.
Racial and ethnic disparities in the treatment and 
management of cardiovascular disease and its risk fac-
tors have long been recognized as major contributors to 
health inequities.6,7 Our study is unique in that it uncov-
ered gaps in care even among Black patients at high 
risk for ASCVD attributable to FH. A prior analysis from 
the CASCADE- FH (Cascade Screening for Awareness 
Table 1. Baseline Characteristics of Patients with 





Number (%) 175 (21.4) 633 (78.6) …
Age, y 56±11 56±15 0.84
Female sex 114 (65%) 399 (63%) 0.67
Treated total cholesterol, mg/dL 202±56 200±61 0.68
Treated LDL- C, mg/dL 127±47 120±53 0.21
Treated HDL- C, mg/dL 54±22 54±17 0.97
Treated triglycerides, mg/dL 44 
(32– 58)
50 (34– 78) 0.002‡
BMI 32±7 29±6 <0.001‡
Hypertension 122 (82) 299 (50) <0.001‡
Current smoking 24 (16) 49 (8) 0.006‡
Diabetes 68 (39) 97 (15) <0.001‡
ASCVD 70 (39) 207 (33) 0.15
Premature ASCVD† 45 (26) 130 (21) 0.17
Statin use 107 (61) 461 (73) 0.004‡
High- intensity statin use 75 (61%) 279 (71) 0.084‡
Ezetimibe use 50 (29) 239 (38) 0.03‡
PCSK9 inhibitor use 2 (1) 78 (13) <0.001‡
ASCVD indicates atherosclerotic cardiovascular disease; BMI, body mass 
index; FH, familial hypercholesterolemia; HDL- C, high- density lipoprotein 
cholesterol; LDL- C, low- density lipoprotein cholesterol; and PCSK9, 
proprotein convertase subtilisin/kexin type 9 serine protease.
*The diagnosis of FH was made based on validated clinical or genetic 
diagnostic criteria. Clinical diagnosis was based on, but was not limited to, 
Simon Broome, Dutch Lipid Clinic Network, MEDPED or American Heart 
Association criteria.
†Premature ASCVD is defined as ASCVD at age <55 in men and <65 in 
women.
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and Detection of Familial Hypercholesterolemia) regis-
try demonstrated that Black patients with FH are nearly 
50% less likely to achieve target LDL- C levels compared 
with patients with FH of EA.8 Our study demonstrated 
no significant differences in on- treatment LDL- C levels, 
but significant disparities in the usage of lipid- lowering 
therapies in Black patients with FH. Reasons for these 
disparities may include patient factors (differences in 
access to care and/or medication adherence attribut-
able to socioeconomic and/or psychological factors), 
provider factors (including treatment biases), and/or 
health system factors.
Our findings extend those of others to show that 
Black patients with FH have multiple traditional risk fac-
tors for ASCVD (hypertension, diabetes, and smoking), 
and this higher risk factor burden is associated with a 
higher prevalence of ASCVD in Black patients with FH. 
Hypertension and cigarette smoking were found to be 
key risk factors for ASCVD in FH patients, suggesting 
that primary and secondary prevention efforts aimed 
at targeting these risk factors could mitigate future 
ASCVD risk in Black patients with FH. Future studies 
might explore the socioeconomic links between medi-
cation usage and nonusage in Black patients with FH, 
whether there may be a benefit from lower therapeu-
tic blood pressure and/or LDL- C targets in this group 
of patients, and which self- management support and 
care delivery strategies lead to greater smoking cessa-
tion rates in Black patients.
Strengths and Limitations
Our study has several limitations. Our analysis was 
retrospective, and residual confounding may have 
contributed to our findings. Additionally, patients in our 
study were selected from specialized preventive car-
diology and lipid clinics around the United States and 
treated by experts within the field and subsequently 
compiled together, which may have introduced 
Table 2. Baseline Characteristics of Patients With Heterozygous FH With and Without ASCVD by Race
Black European ancestry
ASCVD No ASCVD P Value ASCVD No ASCVD P Value
N 68 107 … 207 426
Age, y 56±11 56±11 0.83 62±12 53±16 <0.001*
BMI 31±6 33±8 0.046* 30±7 29±6 0.07
Treated total cholesterol, mg/dL 196±70 201±53 0.25 196±74 202±52 0.27
Treated LDL- C, mg/dL 122±60 121±45 0.88 120±62 121±47 0.84
Treated HDL- C, mg/dL 50±17 56±18 <0.001 50±17 56±16 <0.001*
Treated triglycerides, mg/dL 52 (36– 84) 46 (34– 68) 0.003* 55 (38– 98) 46 (34– 72) <0.001*
Female sex 40 (59) 74 (69) 0.22 103 (50) 296 (70) <0.001*
Hypertension, Y/N (%Y/%N) 59/7 (89/11) 63/19 (77/23) 0.075 161/45 (78/ 22) 138/252 
(35/65)
<0.001*
Current smoking, Y/N (%Y/%N) 17/49 (26/74) 7/75 (9%/92%) 0.009* 21/179 (11/ 90) 27/352 (7/93) 0.21
Diabetes, Y/N (%Y/%N) 30/38 (44/56) 38/69 (36/65) 0.33 56/151 (27/73) 41/385 (10/ 90) <0.001*
ASCVD indicates atherosclerotic cardiovascular disease; BMI, body mass index; FH, familial hypercholesterolemia; HDL- C, high- density lipoprotein 
cholesterol; and LDL- C, low- density lipoprotein cholesterol.
*P value of statistical significance.
Table 3. Mixed Effects Model of the Strongest Predictors of ASCVD for All Patients With Random Site Adjustment
Model 1 Model 2
Odds ratio (95% CI) P Value Odds ratio (95% CI) P Value
Age, y 1.04 (1.03– 1.06) <0.001* Age 1.03 (1.01– 1.04) <0.001*
Black race 1.60 (1.05– 2.44) 0.028* Black race 0.99 (0.96– 1.02) 0.52
Female sex 0.39 (0.28– 0.54) <0.001* Female sex 0.46 (0.32– 0.65) <0.0001*
BMI 0.99 (0.96– 1.02) 0.41
Hypertension 4.09 (2.73– 6.20) <0.0001*
Current smoker 2.69 (1.54– 4.74) 0.001*
Diabetes 1.59 (1.05– 2.42) 0.03*
ASCVD indicates atherosclerotic cardiovascular disease; and BMI, body mass index.
Covariates in model 1 include age, race, and female sex. Covariates in Model 2 include age, race, female sex, BMI, hypertension, current smoking, and 
diabetes.
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selection bias as well as limited the availability of cer-
tain information, including consistent data on plasma 
lipoprotein(a) levels, which are higher among Black 
individuals.9 Furthermore, our relatively small sam-
ple size may have limited our ability to demonstrate 
between- group differences in LDL- C control and/or 
ASCVD as well its risk factors. Of note, ≈23% of pa-
tients in our cohort were not on treatment with lipid- 
lowering therapy. There may be several reasons for 
this: Many of the patients referred to lipid clinics have 
either declined or not been able to tolerate standard 
therapy leading to a much more complex patient pop-
ulation. There are multiple reasons for the lower rates 
of treatment, which include statin intolerance and pa-
tient preference against using lipid- lowering therapy. 
Furthermore, the data presented in the current study 
are cross- sectional in nature. Patients who may not 
have been on lipid- lowering therapy at the time of this 
data collection may have been new to the clinic and 
requested trials of lifestyle modifications initially, fol-
lowed by lipid treatment at a later date. However, a 
strength of our study is that our cohort was enriched 
with Black patients, a demographic group that histori-
cally has been understudied in FH care. To our knowl-
edge, our cohort contains the largest proportion of 
Black patients with FH studied in this manner.10,11 The 
proportional increase in Black patients with FH in our 
cohort likely helped demonstrate differences in their 
usage of lipid- lowering medications and residual risks 
from hypertension and cigarette smoking, which were 
found even though our cohort was receiving care at 
specialized preventive cardiology and lipid clinics. 
Given these findings, one may presume that these ra-
cial disparities are greater among Black patients with 
FH who have inadequate access to either primary or 
lipid specialty care.
Conclusions
FH is a common lipoprotein disorder with an estimated 
prevalence of 1 in 250 US adults, in whom the relative 
risks of cardiovascular morbidity and mortality are 
high. Black patients also have a higher risk of ASCVD 
that has been linked to a higher burden of some physi-
ologic risk factors and to socioeconomic determinants. 
The present study has demonstrated disparities in lipid 
treatment and lipid medication usage in Black patients 
with FH and higher residual risk for future ASCVD in 
this cohort. The latter has been found to be attributa-
ble to racial differences in nearly all modifiable risk fac-
tors for ASCVD, particularly hypertension and cigarette 
smoking, which are highly prevalent and associated 
with elevated risk of ASCVD in Black patients with FH. 
These finding support the need for greater attention to 
lipid medication usage and to reduction in residual risk 
in Black patients with FH through aggressive preven-
tion strategies focused on medication acquisition and 
adherence, smoking cessation, and blood pressure 
management.
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Table S1. Missing Variables.   
 N Missing % Missing 
Age 0 0 
Sex 0 0 
Hypertension 64 8 
Current Smoking 81 10 
Diabetes Mellitus 0 0 
BMI 73 9 
Treated Total Cholesterol 174 22 
Treated LDL-C 173 21 
Treated HDL-C 174 22 
Treated Triglycerides 180 22 
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